Villepinte, 24th april, 2026: GUERBET (FR0000032526 GBT):

Guerbet, a global leader in medical imaging, announces a positive outcome from a worksharing procedure, involving several EU member states, for a new Lipiodol^® indication in interventional radiology. This new indication concerns procedures for peripheral and central vascular embolization with cyanoacrylate-based surgical glues compatible with Lipiodol Ultra Fluid and approved for endovascular use, to allow visualization of the procedure and adjustment of polymerization time.

This represents an important regulatory milestone that will be followed by subsequent national approvals amending the existing marketing authorizations. This step is significant for Lipiodol® within interventional radiology protocols and confirms its clinical relevance in minimally invasive procedures.

A key regulatory advancement across European Community

With this achievement, Lipiodol® moves toward an expanded authorized use, once relevant national approvals obtained, in embolization procedures which will enable healthcare professionals to integrate Lipiodol® within therapeutic strategies with clear instructions for use, on a product known for its radiopacity, controlled viscosity, and compatibility with diverse cyanoacrylate glues approved for endovascular use.

Vascular Embolization: a cornerstone of modern Interventional Radiology

Across Europe, vascular embolization is currently recognized a safe, effective minimally invasive technique in several scientific guidelines[i]. With this new indication, Lipiodol® will allow to perform embolization procedures with cyanoacrylate glue, such as prostate artery embolization in Benign Prostatic Hyperplasia, varicocele or varices treatments, or hemorrhage management, and selected vascular abnormalities.

The data provided to authorities in support of this new indication, demonstrated: 

• Low risk of major complications
• Real‑time imaging guidance supporting procedural precision
• Adaptability to individual anatomic and clinical situations

Francois Convenant SVP Interventional Radiology comments: “This regulatory achievement for Lipiodol® indication in vascular embolization marks a significant milestone for our field. Its radiopacity and physicochemical properties enable more controlled, predictable, and safe embolization procedures. This indication formalizes years of clinical practice and paves the way for harmonizing glue embolization techniques across Europe.”

Scientific Rationale and Clinical Impact

Interventional radiology relies increasingly on embolic agents that offer precision, speed, and durability. In this context, Lipiodol® combined with cyanoacrylate‑based glues provides a controllable, radiopaque liquid embolic agent that enables:

• Real‑time visualization during injection for immediate confirmation of vessel occlusion.
• Adjustable viscosity and polymerization time, allowing clinicians to tailor embolization to both proximal and distal vessels.
• Permanent and effective occlusion, reducing the need for repeat procedures.

A Stronger Commitment to Healthcare Professionals Across European Community

Guerbet reinforces its commitment to support interventional radiology teams throughout the region by offering:

• robust scientific and clinical support,
• dedicated medical education programs,
• strengthened field presence,
• and reliable solutions designed to improve patient care quality and safety, in a cost efficient way for institutions.

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 100 years, with 2,746 employees worldwide, we continuously innovate and devote 10% of our revenue to Research and Development in four centers in France and the United States. Guerbet (GBT) is listed in Compartment B of Euronext Paris and generated revenue of €786 million in 2025. 

For more information, please visit : www.guerbet.com